CKD is estimated to affect more than 850 million people worldwide, and its prevalence is expected to increase with an aging population.1, , –4 For decades, treatment with renin–angiotensin system inhibitors (RASis) has been the mainstay of CKD treatment, with clinical trials showing kidney-protective effects and beneficial cardiovascular risk reduction.5, , –8. The gene discussed is REN; the disease is chronic kidney disease.